In the evolving landscape of global biopharmaceutical investment and R&D demand, the CXO sector has long been stereotyped as a capital-intensive, labor-heavy industry. The market's focus often sticks to the top-line revenue numbers on the first page of financial reports.

However, a deep dive into the financial reports of WUXI APPTEC (02359) from 2025 through the first half of 2026 reveals a clear, bellwether trend: the company's profit growth has consistently and significantly outpaced its revenue growth, creating a widening "gap." From the first quarter of 2025, the difference between adjusted profit growth and revenue growth has been high, running at 19.02%, 27.54%, 26.96%, and 27.16%, before expanding further to 44.3% in the first half of 2026. In other words, the company's efficiency in generating profit from each additional unit of revenue is continuously improving. This signals a shift in the company's growth logic from simple scale expansion to value creation driven by high-value-added businesses.

From "Quantity" to "Quality": High-Value-Added Businesses Unlock Profit Growth Ceilings

This leapfrog growth is not dependent on occasional non-recurring gains. It is rooted in WUXI APPTEC's unique CRDMO integrated business model, the deep optimization of its main revenue structure, and systematic improvements in lean operational efficiency. According to information from Zhitong Finance APP, the source of WUXI APPTEC's high profit margins lies in the profound transformation of its revenue structure, primarily reflected in three dimensions. First, the company's unique "Follow the Molecule" strategy has entered a harvest period after years of cultivation, with the proportion of high-value projects in the overall business steadily increasing. As of the end of June 2026, the company's small molecule D&M pipeline totaled 3,731 projects, with commercial projects rising to 95. These projects, located at the end of the value chain, often have higher profit contribution rates, driving a structural increase in overall margins. Second, the TIDES business has experienced explosive growth, generating revenue of RMB 7.26 billion in the first half of 2026, a year-on-year increase of 44.3%. The company has upgraded its full-year revenue guidance for this segment to around 45% rapid growth. Currently holding a leading position in cutting-edge fields like nucleic acids, conjugates, multispecific antibodies, and peptides, it has become the company's "second growth curve." Finally, the integrated "Biology + Testing" service platform has shown a strong synergistic effect, bringing in over 20% of new customers in the first half of 2026 and continuously feeding a large number of high-value projects to the entire group.

Profit Conversion Capability Soars, Forging a "Cash Cow"-Level HALO Asset

WUXI APPTEC’s second-quarter gross margin (56.56%) and adjusted profit margin (42.36%) both broke historical records. To put this in perspective, using its 38.36% non-GAAP net profit margin as a benchmark, among A-share companies with a quarterly revenue of over RMB 10 billion, almost only finance and high-end liquor giants can maintain profitability at this extreme level. Not only can it "make money," but it can also "collect money." WUXI APPTEC's ability to convert profits into free cash flow is accelerating. In the first half of this year, the company's adjusted non-IFRS profit was RMB 11.57 billion, while its adjusted operating cash flow reached RMB 9.98 billion. This means its operating cash flow accounted for a staggering 86.25% of its profit. What’s more exciting for the market is that as of the end of the second quarter, the company had over RMB 10 billion in accounts receivable on its books. Based on its extremely short collection cycle of about 55 days, the vast majority of this amount is expected to be converted directly into net cash flow in the third quarter. With the continuous improvement in profit and cash flow conversion capabilities, WUXI APPTEC's willingness and execution to reward shareholders are also increasing. Along with its strong interim results, the company announced its second consecutive mid-year dividend, increasing the payout scale to RMB 1.5 billion. This action of sharing high-quality development results with shareholders in cash continues to solidify its value as a core "HALO asset" in the A-share market.

From the widening performance "gap," it is clear that WUXI APPTEC has successfully transitioned from "scale growth" to "value creation." Benefiting from the success of multiple customer products and excellent management execution, the company has raised its full-year 2026 guidance. It expects overall revenue to reach RMB 58.5-60.5 billion, with revenue from continuing operations growing by 35-39% year-on-year. Looking ahead, this high-quality development paradigm, centered on quality and supported by technology, will continue to drive WUXI APPTEC through economic cycles, delivering sustainable, high-quality returns to shareholders and securing a higher level of global competitive advantage.